Group 1 - The company has successfully passed the FDA pre-approval inspection for its commercial production base in Shaoxing, indicating that its quality system is aligned with international standards, enabling it to supply innovative pharmaceutical raw materials to the US and global markets [1] - In the first half of 2025, the company achieved a revenue of 6.441 billion yuan, representing a year-on-year growth of 14.9%, and new orders signed increased by over 10% compared to the previous year, reflecting a recovery in the global biopharmaceutical investment and financing sector [1] - The company maintains its profit forecast, expecting net profits attributable to the parent company to be 1.771 billion yuan, 2.274 billion yuan, and 2.782 billion yuan for 2025-2027, with corresponding EPS of 1.00 yuan, 1.28 yuan, and 1.56 yuan, and the current stock price corresponds to PE ratios of 30.1, 23.5, and 19.2 times [1]